Renueron positive about results of trial with stem cell therapy for stroke survivors

20/12/2016 00:00:00


Bridgend life sciences firm ReNeuron has reported “highly encouraging” latest stage clinical trial results in regained limb movements in stroke sufferers treated with its pioneering stem cell based therapy.

The business has relocated from Surrey to Pencoed following a £25m equity investment from institutional investors, led by the Welsh Government’s Wales Life Sciences Funded managed by Arthurian Life Sciences.

The Pisces stage two trial of its CTX cells for chronic disability caused by strokes, monitored improvement in arm movements.

The aim was to achieve discernible change within three months in two of the 21 patients receiving treatment.

And three patients registered improvement over a variety of timescales, which saw them regaining the ability to lift objects within a year of treatment.

Moreover, 15 patients had “clinically significant response” on at least one of the three commonly used scales for assessing improvements following treatment.

ReNeuron now intends to apply to the US and European regulatory authorities to commence a randomised, placebo-controlled, pivotal clinical trial in patients who are living with disability post stroke.

Professor Sir Christopher Evans, chairman and founder of Arthurian Life Sciences, said: “We are delighted that ReNeuron has reported such encouraging results from its latest study.

"The treatment has great potential for patients and the company will go into its next trial with confidence.

The results of the Pisces II trial are also a real boost for life sciences in Wales.

For more information visit: